RA
TERN

Rise Advisors’s Terns Pharmaceuticals TERN Stock Holding History

Rise Advisors’s Portfolio TERN Stock Details TERN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q4 		– Sell
-445
Closed -$3.34K – 1287
2025
Q3 		$3.34K Buy
445
+83
+23% +$530 ﹤0.01% 1160
2025
Q2 		$1.35K Buy
+362
New +$1.13K ﹤0.01% 1240

Other funds holding TERN

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
Adage Capital Partners
Adage Capital Partners Boston, Massachusetts $64.8B AUM 42.7% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
VC
Vivo Capital Palo Alto, California $1.2B AUM 911.44% 1-Year Est. Return
VPC
Vestal Point Capital New York $3.58B AUM 189.12% 1-Year Est. Return
ACA
Avoro Capital Advisors New York $10.2B AUM 149.19% 1-Year Est. Return
Janus Henderson Group
Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return
CLGM
Capitolis Liquid Global Markets New York $15.7B AUM 30.78% 1-Year Est. Return

Rise Advisors's TERN Position: Q4 2025 in Review

Rise Advisors sold out of Terns Pharmaceuticals (TERN) in Q4 2025, closing a stake of 445 shares — an estimated $3.34K sold.

Rise Advisors first reported a position in TERN in Q2 2025 and held it in 2 quarters. The position peaked at $3.34K in Q3 2025. 248 funds tracked by Wall St. Rank hold TERN as of Q4 2025.

  • Rise Advisors reported no remaining Terns Pharmaceuticals position as of Q4 2025 after selling out during the quarter.
  • Rise Advisors sold 445 Terns Pharmaceuticals shares in Q4 2025, an estimated $3.34K.
  • Rise Advisors first reported a position in Terns Pharmaceuticals in Q2 2025 and held it in 2 quarters.
  • Rise Advisors's Terns Pharmaceuticals position peaked at $3.34K in Q3 2025.
  • 248 funds tracked by Wall St. Rank held Terns Pharmaceuticals as of Q4 2025.

Based on Rise Advisors's 13F filing for Q4 2025, filed 11 Feb 2026.